X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
ARINA-1 is a new nebulized product comprised of ascorbic acid, glutathione, and bicarbonate which is currently being investigated in phase 2 clinical trials for the treatment of patients with Non-cystic Fibrosis Bronchiectasis.
Lead Product(s): Ascorbic Acid,Glutathione,Sodium Bicarbonate
Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: Arina-1
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
The macrogol in Movicol (sodium chloride) binds with water and retains it in the bowel. This allows the water to rehydrate and bulk the stool to trigger renewed colonic activity.
Lead Product(s): Sodium Chloride,Sodium Bicarbonate,Potassium Chloride
Therapeutic Area: Gastroenterology Product Name: Movicol
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Goldman Sachs Asset Management
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing December 15, 2022
Details:
KONVOMEP™ (omeprazole and sodium bicarbonate for oral suspension) is a medication indicated for short-term treatment (4 to 8 weeks) of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill adult patients.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Product Name: Konvomep
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Azurity Pharma
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 07, 2022
Details:
Konvomep™ (omeprazole and sodium bicarbonate for oral suspension) is approved for the treatment of active benign gastric ulcer and reduction of risk of upper gastrointestinal bleeding in critically ill patients.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Product Name: Konvomep
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 02, 2022
Details:
Carlin will be uniquely positioned to acquire and commercialize well-established brands as well as support its retail partners and their customers, in connection with this, Carlin announced the acquisition of Zegerid OTC® (“Zegerid”) from Bayer AG.
Lead Product(s): Omeprazole,Sodium Bicarbonate
Therapeutic Area: Gastroenterology Product Name: Zegerid
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Carlin Consumer Health
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition February 01, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
